SecBot SecBot
6-K ·Filed Apr 1, 2026

APLMW

Apollomics Inc.
MIXED
Impact 6/10
Horizonweeks Processed6mo ago SEC0001193125-26-138117
Notable filing: 6-K
Actionable Insight ◆ Mixed

Monitor for Apollomics' next equity financing announcement, as the $2M note will convert at a 20% discount, creating immediate dilution. The CEO-funded bridge suggests potential difficulty raising capital from external investors, but also demonstrates insider confidence. Watch for subsequent financing activity as the 18-month maturity approaches.

DirectionMixed
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
APLMW ▲ +44.60% at T+60d
NEUTRAL call +44.60% · α vs SPY +30.44% · entry $0.0139 → $0.0201
Entry = T+0 close
Apr 1, 2026
via day close
T+1d
0.00%
call 0.00% · α -0.48%
$0.0139
settled 7mo ago
T+5d
0.00%
call 0.00% · α -3.62%
$0.0139
settled 7mo ago
T+20d
0.00%
call 0.00% · α -9.88%
$0.0139
settled 6mo ago
T+60d
+44.60%
call +44.60% · α +30.44%
$0.0201
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

Apollomics Inc. issued a $2 million unsecured, zero-interest convertible promissory note to its CEO, Hung-Wen Chen, as bridge financing. The note will automatically convert into equity at an 80% discount to the next qualified financing round of at least $10 million. This related-party transaction provides short-term liquidity but introduces future dilution risk.

Key Facts

  • Apollomics issued a $2,000,000 convertible promissory note to CEO Hung-Wen Chen on March 30, 2026
  • The note bears 0% interest and is unsecured
  • Principal will automatically convert into equity upon next financing round raising at least $10,000,000
  • Conversion price will be 80% of the lowest per-share price in the next equity financing
  • If not converted by maturity (18 months), CEO can convert at average market price over 10 trading days prior
  • Transaction was approved by independent Audit Committee and Board with CEO abstaining

Financial Impact

$2,000,000 bridge financing with potential for significant dilution upon conversion at 20% discount to next equity round

cashFlowdilutiondebt

Risk Factors

  • Future dilution will be significant when the note converts at 20% discount to next financing
  • Reliance on CEO funding may indicate challenges in raising capital from external investors
  • If no qualifying financing occurs within 18 months, the company may face liquidity constraints

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001193125-26-138117
Document: d142784d6k.htm0001193125-26-138117
Document: d142784dex991.htm0001193125-26-138117
Document: 0001193125-26-138117-index-headers.html0001193125-26-138117
Document: 0001193125-26-138117-index.html0001193125-26-138117
Document: 0001193125-26-138117.txt0001193125-26-138117
4 reports for APLMW
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for APLMW — sortable, filterable
TypeNow
Jun 3, 2026
20w ago
EFFECT
BEARISH ★ 5/10
$0.0139 $0.0143▼ −2.88%▼ −0.38%—
Apr 27, 2026
26w ago
6-K
MIXED ★ 6/10
$0.0139 $0.0175▲ +25.90%▲ +21.12%—
Apr 24, 2026
26w ago
20-F
BEARISH ★ 7/10
$0.0139 $0.0175▼ −25.90%▼ −21.12%—
Apr 1, 2026
29w ago
6-K
MIXED ★ 6/10
$0.0139 $0.0201▲ +44.60%▲ +30.44%—
Showing 4 of 4

US Market Status

Market Closed — Opens Thu (12h 10m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 1, 2026